Skip to Main Content

Paper Details

A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.
Rare Tumors
14
2018
Author NameAffiliation
Nam BuiStanford Cancer Institute
  • 1 - 1

Datasets

Release 1.2